BRPI0912337A2 - composto método para melhorar memória em paciente, e, método para tratar condições - Google Patents

composto método para melhorar memória em paciente, e, método para tratar condições

Info

Publication number
BRPI0912337A2
BRPI0912337A2 BRPI0912337A BRPI0912337A BRPI0912337A2 BR PI0912337 A2 BRPI0912337 A2 BR PI0912337A2 BR PI0912337 A BRPI0912337 A BR PI0912337A BR PI0912337 A BRPI0912337 A BR PI0912337A BR PI0912337 A2 BRPI0912337 A2 BR PI0912337A2
Authority
BR
Brazil
Prior art keywords
treating conditions
improving patient
patient memory
compound
compound method
Prior art date
Application number
BRPI0912337A
Other languages
English (en)
Inventor
Nikolich Karoly
Nadasdi Laszlo
Original Assignee
Amnestix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amnestix Inc filed Critical Amnestix Inc
Publication of BRPI0912337A2 publication Critical patent/BRPI0912337A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912337A 2008-05-12 2009-05-11 composto método para melhorar memória em paciente, e, método para tratar condições BRPI0912337A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5260008P 2008-05-12 2008-05-12
PCT/US2009/043464 WO2009151845A1 (en) 2008-05-12 2009-05-11 Compounds for rho kinase inhibition and for improving learning and memory

Publications (1)

Publication Number Publication Date
BRPI0912337A2 true BRPI0912337A2 (pt) 2019-09-24

Family

ID=41319017

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0912386A BRPI0912386A2 (pt) 2008-05-12 2009-05-11 composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase
BRPI0912337A BRPI0912337A2 (pt) 2008-05-12 2009-05-11 composto método para melhorar memória em paciente, e, método para tratar condições

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0912386A BRPI0912386A2 (pt) 2008-05-12 2009-05-11 composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase

Country Status (10)

Country Link
US (3) US20110294789A1 (pt)
EP (2) EP2285217A4 (pt)
JP (2) JP2011519973A (pt)
KR (2) KR20110011669A (pt)
CN (2) CN102316737A (pt)
AU (2) AU2009246568A1 (pt)
BR (2) BRPI0912386A2 (pt)
CA (2) CA2725416A1 (pt)
MX (2) MX2010012103A (pt)
WO (2) WO2009151845A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US8703736B2 (en) * 2011-04-04 2014-04-22 The Translational Genomics Research Institute Therapeutic target for pancreatic cancer cells
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
JP6509747B2 (ja) * 2013-03-04 2019-05-08 ヘルス・サイエンシズ・ノース・リサーチ・インスティチュート キノリンスルホニル誘導体及びそれらの使用
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
WO2015070170A1 (en) * 2013-11-08 2015-05-14 The Translational Genomics Research Institute Compounds for cognitive enhancement and methods of use thereof
CN105085478B (zh) * 2014-04-28 2019-04-12 南京明德新药研发股份有限公司 异喹啉磺胺衍生物及其药物组合物和制药用途
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
EP4198031A1 (en) * 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
ES2927542T3 (es) * 2017-07-19 2022-11-08 China Resources Pharmaceutical Holdings Company Ltd Derivado de isoquinolinilsulfonilo y uso del mismo
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
EP3868408A4 (en) 2018-10-15 2022-07-06 National University Corporation Tokai National Higher Education and Research System Antipsychotic and use thereof
MX2022008513A (es) 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
CA3169944A1 (en) * 2020-03-25 2021-09-30 Thomas Macallister Methods of using rho kinase inhibitors to treat frontotemporal dementia
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
CN116249532A (zh) * 2020-06-15 2023-06-09 乌尔塞制药公司 使用Rho激酶抑制剂治疗血管性痴呆的方法
MX2022016336A (es) * 2020-06-25 2023-01-24 Woolsey Pharmaceuticals Inc Metodos de tratamiento de trastornos del neurodesarrollo.
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
WO2022046158A1 (en) * 2020-08-27 2022-03-03 Woolsey Pharmaceuticals, Inc Methods of treating age-related cognitive decline
MX2023002396A (es) * 2020-08-28 2023-05-10 Woolsey Pharmaceuticals Inc Métodos para tratar el deterioro cognitivo relacionado con la edad.
EP4232041A4 (en) * 2020-10-22 2024-09-25 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456757A (en) * 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
US4678783B1 (en) * 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
WO2000003746A2 (en) * 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
WO2004058717A1 (en) * 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
WO2005117896A1 (de) * 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
CA2621181C (en) * 2005-08-30 2011-04-19 Asahi Kasei Pharma Corporation 5-isoquinolinesulfonamide compounds
JP5052518B2 (ja) * 2005-10-06 2012-10-17 シェーリング コーポレイション プロテインキナーゼインヒビターとしてのピラゾロピリミジン
WO2008019395A2 (en) * 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
EP2285217A4 (en) * 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY

Also Published As

Publication number Publication date
EP2285217A1 (en) 2011-02-23
KR20110011669A (ko) 2011-02-08
CA2723472A1 (en) 2009-12-17
EP2296472A1 (en) 2011-03-23
MX2010012104A (es) 2011-04-05
US20110237600A1 (en) 2011-09-29
CN102316737A (zh) 2012-01-11
US20110294789A1 (en) 2011-12-01
WO2009151845A1 (en) 2009-12-17
EP2285217A4 (en) 2011-06-08
CN102088853A (zh) 2011-06-08
JP2011519972A (ja) 2011-07-14
BRPI0912386A2 (pt) 2016-07-26
US20100160297A1 (en) 2010-06-24
KR20110014183A (ko) 2011-02-10
CA2725416A1 (en) 2009-11-19
JP2011519973A (ja) 2011-07-14
AU2009257926A1 (en) 2009-12-17
WO2009140200A1 (en) 2009-11-19
MX2010012103A (es) 2011-04-04
WO2009151845A9 (en) 2010-01-28
EP2296472A4 (en) 2011-06-08
AU2009246568A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
BRPI0912337A2 (pt) composto método para melhorar memória em paciente, e, método para tratar condições
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI0916472A2 (pt) dispositivo de tratamento de ferimento, método para tratamento de um ferimento e dispositivo de tratamento de ferimento
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BR112013009935A2 (pt) compostos, composição, método e semente tratada
IL232222A0 (en) Methods for treating progressive multiple sclerosis
BRPI0910969A2 (pt) dispositivo, método para preparar em dispositivo, e, método para tratar um paciente
BRPI0909627A2 (pt) métodos, composições e kits para tratar dores e pruridos
BRPI0913227A2 (pt) método, e objeto
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
SMT201500171B (it) Metodo per trattare la fibrillazione atriale
BRPI0807216A2 (pt) Fluido de tratamento, e, método para tratar uma formação subterrânea
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0919576A2 (pt) Composto de piperazina, e, método para controlar vegetação indesejada
BR112012004180A2 (pt) método para tratar uma formação subterrânea, e, dispositivo de ativação
BRPI0823277A2 (pt) Composição, e , método
BRPI0815283A2 (pt) Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0908715A2 (pt) métodos para tratamento da psoríase
BRPI0918736A2 (pt) método para produzir leite modificado.
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente
BRPI0822472A2 (pt) Método, camundongo, e, composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.